Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atrasentan (Primary)
Indications IgA nephropathy
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ALIGN
Sponsors Chinook Therapeutics

Most Recent Events

20 Mar 2025 According to a Novartis media release, the company announced that a decision on FDA filling is anticipated in H1 2025.
27 Oct 2024 According to a Novartis media release, atrasentan received FDA filing acceptance in Q2 2024.
15 Aug 2024 Planned primary completion date changed from 1 Dec 2023 to 18 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com